Vincerx Pharma, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OTC.Pink
Sage Rhino Capital, LLC has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Vincerx Pharma, Inc., which is noted as pending dissolution.
OTC.Pink
SCHEDULE 13G/A: Armistice Capital Reduces Stake in Vincerx Pharma to Below 5%
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% in Vincerx Pharma, Inc.'s Common Stock.
OTC.Pink
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in Vincerx Pharma, Inc. as of December 31, 2024.
OTC.Pink
Prosight Management, LP and affiliated entities have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% in Vincerx Pharma, Inc. as of December 31, 2024, primarily through warrants with conversion restrictions.
OTC.Pink
An investment group led by Long Focus Capital Management, LLC has filed a final amendment to its Schedule 13G, indicating its beneficial ownership in Vincerx Pharma, Inc. common stock has decreased to 0% as of December 31, 2024.